| 基于真实世界数据的EGFRIs治疗相关皮肤干燥不良反应的流行病学调查 |
| |
| 引用本文： | 鲁星妤,刘 喆,张予辉,邢镨元,张静怡,薛崇祥,李 嘉,俞仪萱,崔慧娟.基于真实世界数据的EGFRIs治疗相关皮肤干燥不良反应的流行病学调查[J].现代肿瘤医学,2021,0(20):3644-3648. |
| |
| 作者姓名： | 鲁星妤 刘 喆 张予辉 邢镨元 张静怡 薛崇祥 李 嘉 俞仪萱 崔慧娟 |
| |
| 作者单位： | 1.北京中医药大学，北京 100020;2.北京胸科医院，北京 101149;3.北京朝阳医院，北京 100027;4.中国医学科学院肿瘤医院，北京 100021;5.中日友好医院中西医结合肿瘤内科，北京 100029 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81873396）;国家自然科学基金面上项目（编号:81873396）；首都卫生发展科研专项（编号:2018-2-4065） |
| |
| 摘 要： | 目的:观察表皮生长因子抑制剂（epidermal growth factor receptor inhibitors，EGFRIs）治疗相关皮肤干燥的发生率，探讨年龄、性别、靶向药物种类等因素与EGFRIs相关皮肤干燥发生的相关性，并调研该不良反应既往接受治疗的疗效及特征。方法:对2020年11月24日至2021年1月14日在中日友好医院等多家医院就诊的肿瘤患者进行问卷调查。应用SPSS 21.0软件，采用Pearson卡方检验、Fisher确切概率法对数据进行相关性分析。结果:EGFRIs相关皮肤干燥的发生率为70.9%，且有44.2%的患者发生了至少Ⅱ级(常见不良反应事件评价标准 5.0)的干燥相关不良反应。EGFRIs相关皮肤干燥的发生率在年龄、性别、EGFR基因突变类型上均无统计学差异，靶向药物种类在皮肤干燥发生率方面具有统计学差异（P=0.009），阿法替尼的发生率最高(P=0.005)。是否接受治疗与患者的年龄、性别无关(P=0.969，P=0.694)，而是否伴有瘙痒和脱屑对患者是否接受治疗有显著影响。结论:基于真实世界数据，EGFRIs相关皮肤干燥的发生率高达70.9%，该不良反应的发生和治疗值得关注并进一步研究。
|
| 关 键 词： | EGFRIs 皮肤干燥发生率 皮肤毒性 |
Epidemiological investigation of EGFRIs-related xerosis based on the real world data |
| |
| LU Xingyu,LIU Zhe,ZHANG Yuhui,XING Puyuan,ZHANG Jingyi,XUE Chongxiang,LI Jia,YU Yixuan,CUI Huijuan.Epidemiological investigation of EGFRIs-related xerosis based on the real world data[J].Journal of Modern Oncology,2021,0(20):3644-3648. |
| |
| Authors: | LU Xingyu LIU Zhe ZHANG Yuhui XING Puyuan ZHANG Jingyi XUE Chongxiang LI Jia YU Yixuan CUI Huijuan |
| |
| Affiliation: | 1.Beijing University of Chinese Medicine,Beijing 100020,China;2.Beijing Chest Hospital,Beijing 101149,China;3.Beijing Chao-Yang Hospital,Beijing 100027,China;4.Cancer Hospital Chinese Academy of Medical Sciences,Beijing 100021,China;5.Deparment of Inegrative Oncology,China-Japan Friendship Hospital,Beijing 100029,China. |
| |
| Abstract: | Objective:To observe the incidence of epidermal growth factor receptor inhibitors(EGFRIs)-related xerosis in tumor patients using EGFR-targeted drugs,and to explore the correlation between age,gender,type of targeted drugs and other factors and the incidence of EGFRIs-related xerosis,and to investigate the efficacy and treatment characteristic of EGFRIs-related xerosis.Methods:A questionnaire survey was conducted among tumor patients who visited several hospitals including China-Japan Friendship Hospital from November 24,2020 to January 14,2021.Pearson chi-square test and Fisher exact probability method were used to analyse the correlation by SPSS 21.0 software.Results:The statistics finding showed that 70.9% of patients had the xerosis during EGFRIs administration,and 44.2% of patients had at least a grade Ⅱ(Common Terminology Criteria for Adverse Events 5.0)xerosis.There was no statistical difference in the incidence of EGFRIS-related xerosis by age,gender,and EGFR gene mutation type.The types of targeted drugs had statistically significant differences in the occurrence of xerosis(P=0.009),and Afatinib had the highest incidence of xerosis according to Pearson chi-square test(P=0.005).Whether patients received treatment or not was not related to the age and gender of patients (P=0.969,P=0.694).The presence or absence of pruritus and desquamation had a significant effect on whether patients received treatment or not.Conclusion:The incidence of xerosis associated with EGFRIs is as high as 70.9% in the real world study.The occurrence and treatment of this EGFRIs-related adverse event deserve more attention and further research. |
| |
| Keywords: | EGFRIs the incidence of EGFRIs-related xerosis cutaneous toxicity |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
